Mariëtte Labots

3.3k citations
60 papers · 1.1k · h-index 17

Impact in

  • Cancer Research top 5%
    • Cancer Genomics and Diagnostics
  • Oncology top 5%
    • Colorectal Cancer Treatments and Studies
    • Pancreatic and Hepatic Oncology Research

Papers in

  • Oncology 33
    • Colorectal Cancer Treatments and Studies 13
    • Cancer Immunotherapy and Biomarkers 8
    • Pancreatic and Hepatic Oncology Research 7
  • Molecular Biology 25
    • Melanoma and MAPK Pathways 7
    • PI3K/AKT/mTOR signaling in cancer 6
Co-authors
Henk M.W. Verheul (39 shared papers)Henk Dekker (11 shared papers)Connie R. Jiménez (15 shared papers)Sander R. Piersma (12 shared papers)Godefridus J. Peters (7 shared papers)Richard J. Honeywell (7 shared papers)Henk J. Broxterman (4 shared papers)Richard R. de Haas (3 shared papers)
Journals
Journal of Clinical Oncology (6 papers)Annals of Oncology (5 papers)Cancer Research (4 papers)Nature Communications (3 papers)Cancers (3 papers)
Partner nations
NetherlandsUnited StatesUnited Kingdom

In The Last Decade

Mariëtte Labots

53 papers receiving 1.1k citations

Peers

Mariëtte Labots
Comparison fields: 5 of 87
  • Cancer Research 329
  • Oncology 457
  • Pulmonary and Respiratory Medicine 296
  • Molecular Biology 576
  • Spectroscopy 117
Replace Maeva Dufies with:
Maeva Dufies France
Lydia Sánchez Spain
Luigi Portella Italy
Stephanie M. McGregor United States
Wassim Abida United States
Kristopher K. Frese United Kingdom
José Jiménez Spain
Brian Higgins United States
Kazuki Yamanaka Japan
Mariëtte Labots relative to Maeva Dufies France Maeva Dufies's profile →
Citations per field
00.5×2×4×6×7.3×
Maeva Dufies · 1×
Citations per year

Countries citing papers authored by Mariëtte Labots

Since Specialization
Citations

This map shows the geographic impact of Mariëtte Labots's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mariëtte Labots with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mariëtte Labots more than expected).

Fields of papers citing papers by Mariëtte Labots

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mariëtte Labots. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mariëtte Labots. The network helps show where Mariëtte Labots may publish in the future.

Co-authors

The 25 scholars most cited alongside Mariëtte Labots, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mariëtte Labots Line = papers co-authored together Mariëtte Labots links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 60 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
Clinical Cancer Research ·Kristy J. Gotink, Henk J. Broxterman, Mariëtte Labots, Richard R. de Haas, Henk Dekker, Richard J. Honeywell, Michelle A. Rudek, Laurens V. Beerepoot, René J. P. Musters, Gerrit Jansen, Arjan W. Griffioen, Yehuda G. Assaraf, Роберто Пили, Godefridus J. Peters, Henk M.W. Verheul
2011290
2
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies
Nature Genetics ·Lindsay Angus, Marcel Smid, Saskia M. Wilting, Job van Riet, Arne van Hoeck, Luan Nguyen, Serena Nik‐Zainal, Tessa G. Steenbruggen, Vivianne C. G. Tjan‐Heijnen, Mariëtte Labots, J.M.G.H. van Riel, Haiko J. Bloemendal, Neeltje Steeghs, Martijn P. Lolkema, Emile E. Voest, Harmen J.G. van de Werken, Agnes Jager, Edwin Cuppen, Stefan Sleijfer, John W.M. Martens
2019202
3
INKA , an integrative data analysis pipeline for phosphoproteomic inference of active kinases
Molecular Systems Biology ·Robin Beekhof, Carolien van Alphen, Alex A. Henneman, Jaco C. Knol, Thang V. Pham, Frank Rolfs, Mariëtte Labots, Evan Henneberry, Tessa YS Le Large, Richard R. de Haas, Sander R. Piersma, Valentina Vurchio, Andrea Bertotti, Livio Trusolino, Henk M.W. Verheul, Connie R. Jiménez
201959
4
Therapeutic Drug Monitoring to Individualize the Dosing of Pazopanib
Therapeutic Drug Monitoring ·Djoeke de Wit, Nielka P. van Erp, Jan den Hartigh, Ron Wolterbeek, Margret den Hollander-van Deursen, Mariëtte Labots, Henk‐Jan Guchelaar, Henk M.W. Verheul, Hans Gelderblom
201450
5
Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features
Nature Communications ·Pauline A.J. Mendelaar, Marcel Smid, Job van Riet, Lindsay Angus, Mariëtte Labots, Neeltje Steeghs, Mathijs P. Hendriks, Geert A. Cirkel, Johan M. van Rooijen, Albert J. ten Tije, Martijn P. Lolkema, Edwin Cuppen, Stefan Sleijfer, John W.M. Martens, Saskia M. Wilting
202145
6
Genomic landscape of metastatic colorectal cancer
Nature Communications ·Josien Haan, Mariëtte Labots, Christian Rausch, Miriam Koopman, Jolien Tol, Leonie J. Mekenkamp, Mark A. van de Wiel, Daniëlle Israeli, Hendrik F. van Essen, Nicole C.T. van Grieken, Quirinus J.M. Voorham, Linda J.W. Bosch, Xueping Qu, Omar Kabbarah, Henk M.W. Verheul, Irıs D. Nagtegaal, Cornelis J.A. Punt, Bauke Ylstra, Gerrit A. Meijer
201445
7
Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines
Journal of Proteomics ·Sander R. Piersma, Jaco C. Knol, Inge de Reus, Mariëtte Labots, Bharath Sampadi, Thang V. Pham, Yasushi Ishihama, Henk M.W. Verheul, Connie R. Jiménez
201543
8
Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics
Journal of Proteomics ·Johannes C. van der Mijn, Mariëtte Labots, Sander R. Piersma, Thang V. Pham, Jaco C. Knol, Henk J. Broxterman, Henk M.W. Verheul, Connie R. Jiménez
201539
9
Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection
Journal of Proteomics ·Mariëtte Labots, Johannes C. van der Mijn, Robin Beekhof, Sander R. Piersma, Richard R. de Goeij‐de Haas, Thang V. Pham, Jaco C. Knol, Henk Dekker, Nicole C.T. van Grieken, Henk M.W. Verheul, Connie R. Jiménez
201726
10
Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells
Current Pharmaceutical Design ·Elisa Giovannetti, Mariëtte Labots, Henk Dekker, Elena Galvani, Joline S.W. Lind, Rocco Sciarrillo, Richard J. Honeywell, Egbert F. Smit, Henk M.W. Verheul, Godefridus J. Peters
201225
11
Sex- and site-specific differences in colorectal cancer risk among people with type 2 diabetes
International Journal of Colorectal Disease ·Jetty A. Overbeek, Josephina G. Kuiper, Amber A. van der Heijden, Mariëtte Labots, Ulrike Haug, Ron M. C. Herings, Giel Nijpels
201824
12
Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods
Analytical and Bioanalytical Chemistry ·Sander R. Piersma, Mariëtte Labots, Henk M.W. Verheul, Connie R. Jiménez
201024
13
Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
Experimental & Molecular Medicine ·Mariëtte Labots, Kristy J. Gotink, Henk Dekker, Kaamar Azijli, Johannes C. van der Mijn, Charlotte M. Huijts, Sander R. Piersma, Connie R. Jiménez, Henk M.W. Verheul
201621
14
Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer
Science Translational Medicine ·Robin Beekhof, Andrea Bertotti, Franziska Böttger, Valentina Vurchio, Francesca Cottino, Eugenia R. Zanella, Giorgia Migliardi, Marco Viviani, Elena Grassi, Barbara Lupo, Alex A. Henneman, Jaco C. Knol, Thang V. Pham, Richard de Goeij-de Haas, Sander R. Piersma, Mariëtte Labots, Henk M.W. Verheul, Livio Trusolino, Connie R. Jiménez
202317
15
Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results.
Journal of Clinical Oncology ·Howard Safran, Philippe A. Cassier, Cécile Vicier, Frédéric Forget, Carlos Gomez‐Roca, Nicolas Penel, Mario Campone, Emanuela Romano, Jennifer Brooke Valerin, Guy Jérusalem, Anthony B. El-Khoueiry, Matt D. Galsky, Débora S. Bruno, David Schröder, Mariëtte Labots, Stefano Rinaldi, Amy D. Holdorf, Violetta Kivovich, Jean-Marie Cuillerot, Vivek Subbiah
202317
16
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol
The Lancet Regional Health - Europe ·Karlijn Verkerk, Birgit S. Geurts, Laurien J. Zeverijn, Vincent van der Noort, Henk M.W. Verheul, John B.A.G. Haanen, Astrid A.M. van der Veldt, Ferry A.L.M. Eskens, Maureen J.B. Aarts, Carla M.L. van Herpen, Mathilde Jalving, Jourik A. Gietema, Lot A. Devriese, Mariëtte Labots, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Egbert F. Smit, Haiko J. Bloemendal
202416
17
Mass Spectrometry-Based Serum and Plasma Peptidome Profiling for Prediction of Treatment Outcome in Patients With Solid Malignancies
The Oncologist ·Mariëtte Labots, Lisette M. Schütte, Johannes C. van der Mijn, Thang V. Pham, Connie R. Jiménez, Henk M.W. Verheul
201416
18
Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors
Journal of Clinical Oncology ·Maria Rovithi, Sophie L. Gerritse, Richard J. Honeywell, Albert J. ten Tije, Rita Ruijter, Godefridus J. Peters, Jens Voortman, Mariëtte Labots, Henk M.W. Verheul
201813
19
High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection
Cellular Oncology ·Mariëtte Labots, Tineke E. Buffart, Josien Haan, Nicole C.T. van Grieken, Marianne Tijssen, Cornelis J.�H. van de Velde, Heike I. Grabsch, Bauke Ylstra, Beatriz Carvalho, Remond J.A. Fijneman, Henk M.W. Verheul, Gerrit A. Meijer
201313
20
Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome
Cancers ·Mariëtte Labots, Thang V. Pham, Richard J. Honeywell, Jaco C. Knol, Robin Beekhof, Richard de Goeij-de Haas, Henk Dekker, Maarten Neerincx, Sander R. Piersma, Johannes C. van der Mijn, Donald L. van der Peet, Martijn R. Meijerink, Godefridus J. Peters, Nicole C.T. van Grieken, Connie R. Jiménez, Henk M.W. Verheul
202012

About Mariëtte Labots

Mariëtte Labots is a scholar working on Oncology, Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine and Spectroscopy, having authored 60 papers that have together received 1.1k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (16 papers), Colorectal Cancer Treatments and Studies (13 papers), Advanced Proteomics Techniques and Applications (9 papers), Renal cell carcinoma treatment (8 papers), Cancer Immunotherapy and Biomarkers (8 papers), Melanoma and MAPK Pathways (7 papers), Pancreatic and Hepatic Oncology Research (7 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). The work is most often cited by research in Cancer Research (329 citations), Oncology (457 citations), Pulmonary and Respiratory Medicine (296 citations), Molecular Biology (576 citations) and Spectroscopy (117 citations). Mariëtte Labots has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Henk M.W. Verheul, Henk Dekker, Connie R. Jiménez, Sander R. Piersma, Godefridus J. Peters, Richard J. Honeywell, Henk J. Broxterman, Richard R. de Haas, Kristy J. Gotink and Thang V. Pham. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Nature Communications and Cancers.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maeva DufiesBreakdown of academic impact, for papers by Lydia SánchezBreakdown of academic impact, for papers by Luigi PortellaBreakdown of academic impact, for papers by Stephanie M. McGregorBreakdown of academic impact, for papers by Wassim AbidaBreakdown of academic impact, for papers by Kristopher K. FreseBreakdown of academic impact, for papers by José JiménezBreakdown of academic impact, for papers by Brian HigginsBreakdown of academic impact, for papers by Kazuki Yamanaka